Oak Therapeutics Announces Results of Bioequivalence Study of Company’s Oral Dissolvable Strip for Tuberculosis

Results of In Vivo Study Signifies Completion of another Critical Milestone in Company’s Phase I of NIAID Contract* to Develop ODS Strip for Anti-Tuberculosis Treatment Option OXNARD, Calif., Oct. 03, 2017, CURR, (GLOBE NEWSWIRE) Oak Therapeutics, a subsidiary of CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology company, has completed an in vivo study that compared the pharmacokinetics of its proprietary 300mg Isoniazid (INH) oral dissolvable strip (ODS) as an anti-tuberculosis (TB) treatment option against an existing
http://bit.ly/2wvF0WY